MCID: INV004
MIFTS: 35

Invasive Bladder Transitional Cell Carcinoma malady

Categories: Cancer diseases, Nephrological diseases

Aliases & Classifications for Invasive Bladder Transitional Cell Carcinoma

Aliases & Descriptions for Invasive Bladder Transitional Cell Carcinoma:

Name: Invasive Bladder Transitional Cell Carcinoma 12 14
Infiltrating Bladder Urothelial Carcinoma 69
Invasive Bladder Urothelial Carcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:6477
NCIt 47 C27885
UMLS 69 C1334281

Summaries for Invasive Bladder Transitional Cell Carcinoma

MalaCards based summary : Invasive Bladder Transitional Cell Carcinoma, also known as infiltrating bladder urothelial carcinoma, is related to non-invasive bladder urothelial carcinoma and transitional cell carcinoma, and has symptoms including dysuria An important gene associated with Invasive Bladder Transitional Cell Carcinoma is NOTCH1 (Notch 1), and among its related pathways/superpathways are MicroRNAs in cancer and DNA Damage. The drugs Cisplatin and Carboplatin have been mentioned in the context of this disorder. Related phenotypes are Increased shRNA abundance (Z-score > 2) and digestive/alimentary

Related Diseases for Invasive Bladder Transitional Cell Carcinoma

Diseases related to Invasive Bladder Transitional Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 34)
id Related Disease Score Top Affiliating Genes
1 non-invasive bladder urothelial carcinoma 12.2
2 transitional cell carcinoma 10.2
3 congenital sucrase-isomaltase deficiency without sucrose intolerance 10.2 NOTCH1 TP53
4 brain stem medulloblastoma 10.2 NOTCH1 TP53
5 cutaneous adenocystic carcinoma 10.1 NOTCH1 TP53
6 duodenal ulcer 10.1 NOTCH1 TP53
7 fallopian tube benign neoplasm 10.1 NOTCH1 TP53
8 acute mountain sickness 10.1 CDKN1A TP53
9 inverted follicular keratosis 10.1 CDKN1A TP53
10 scarlet fever 10.1 CDKN1A TP53
11 perineural angioma 10.1 CDKN1A TP53
12 cervical verrucous carcinoma 10.1 CDKN1A TP53
13 toxic megacolon 10.1 CDKN1A TP53
14 gallbladder papillomatosis 10.1 CDKN1A TP53
15 malignant spindle cell melanoma 10.1 CDKN1A TP53
16 traumatic brain injury 10.1 NOTCH1 TP53
17 fallopian tube adenocarcinoma 10.1 CDKN1A TP53
18 maxillary sinus cholesteatoma 10.1 CDKN1A TP53
19 extraocular retinoblastoma 10.0 CDKN1A TP53
20 type 1 papillary adenoma of the kidney 10.0 TP53 UPK3A
21 integumentary system benign neoplasm 10.0 CDKN1A TP53
22 uterine corpus endometrial stromal sarcoma 10.0 TP53 UPK3A
23 lattice corneal dystrophy 10.0 CDKN1A TP53
24 prostate cancer, hereditary, x-linked 1 10.0 CDKN1A TP53
25 secondary hyperparathyroidism of renal origin 10.0 TP53 UPK3A
26 ocular melanoma 10.0 CDKN1A NOTCH1 TP53
27 plague 9.9 CDKN1A TP53
28 splenic infarction 9.9 TP53 UPK3A
29 post-surgical hypoinsulinemia 9.9 CDKN1A TP53
30 bladder urothelial carcinoma 9.8
31 papillary transitional carcinoma 9.8 KIF11 TP53 UPK3A
32 dysembryoplastic neuroepithelial tumor 9.8 CDKN1A TP53 UPK3A
33 ladd syndrome 9.8 CDKN1A TP53 UPK3A
34 breast epithelioid hemangioma 9.2 CDKN1A HOXA13 KIF11 NOTCH1 TP53 UPK3A

Graphical network of the top 20 diseases related to Invasive Bladder Transitional Cell Carcinoma:



Diseases related to Invasive Bladder Transitional Cell Carcinoma

Symptoms & Phenotypes for Invasive Bladder Transitional Cell Carcinoma

UMLS symptoms related to Invasive Bladder Transitional Cell Carcinoma:


dysuria

GenomeRNAi Phenotypes related to Invasive Bladder Transitional Cell Carcinoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-108 9.62 CDKN1A
2 Increased shRNA abundance (Z-score > 2) GR00366-A-12 9.62 TP53
3 Increased shRNA abundance (Z-score > 2) GR00366-A-120 9.62 TP53
4 Increased shRNA abundance (Z-score > 2) GR00366-A-132 9.62 TP53
5 Increased shRNA abundance (Z-score > 2) GR00366-A-169 9.62 TP53
6 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.62 HOXA13
7 Increased shRNA abundance (Z-score > 2) GR00366-A-178 9.62 HOXA13
8 Increased shRNA abundance (Z-score > 2) GR00366-A-19 9.62 HOXA13 TP53
9 Increased shRNA abundance (Z-score > 2) GR00366-A-190 9.62 TP53
10 Increased shRNA abundance (Z-score > 2) GR00366-A-210 9.62 HOXA13
11 Increased shRNA abundance (Z-score > 2) GR00366-A-22 9.62 HOXA13
12 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.62 CDKN1A
13 Increased shRNA abundance (Z-score > 2) GR00366-A-35 9.62 TP53
14 Increased shRNA abundance (Z-score > 2) GR00366-A-39 9.62 HOXA13 TP53 CDKN1A
15 Increased shRNA abundance (Z-score > 2) GR00366-A-50 9.62 CDKN1A
16 Increased shRNA abundance (Z-score > 2) GR00366-A-76 9.62 CDKN1A
17 Increased shRNA abundance (Z-score > 2) GR00366-A-88 9.62 CDKN1A

MGI Mouse Phenotypes related to Invasive Bladder Transitional Cell Carcinoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.46 HOXA13 NOTCH1 TP53 CDKN1A
2 embryo MP:0005380 9.35 HOXA13 KIF11 NOTCH1 TP53 CDKN1A
3 renal/urinary system MP:0005367 9.02 NOTCH1 TP53 UPK3A CDKN1A HOXA13

Drugs & Therapeutics for Invasive Bladder Transitional Cell Carcinoma

Drugs for Invasive Bladder Transitional Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 123)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 3,Phase 2,Phase 1,Early Phase 1 15663-27-1 84093 441203 2767
2
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
3
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
4
Fluorouracil Approved Phase 3,Phase 2 51-21-8 3385
5
Valrubicin Approved Phase 3,Phase 2 56124-62-0 41744
6
Mannitol Approved, Investigational Phase 3,Phase 2 69-65-8 453 6251
7
Doxorubicin Approved, Investigational Phase 3,Phase 2 23214-92-8 31703
8
Vinblastine Approved Phase 3,Phase 2 865-21-4 13342 241903
9
Paclitaxel Approved, Vet_approved Phase 3,Phase 1,Phase 2 33069-62-4 36314
10
Methotrexate Approved Phase 3,Phase 2 1959-05-2, 59-05-2 126941
11
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
12
Bevacizumab Approved, Investigational Phase 3,Phase 2 216974-75-3
13
Ethanol Approved Phase 3 64-17-5 702
14
nivolumab Approved Phase 3,Phase 2 946414-94-4
15
Succinylcholine Approved Phase 3 306-40-1 5314
16
leucovorin Approved, Nutraceutical Phase 3,Phase 2 58-05-9 54575, 6560146 143
17
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2 59-30-3 6037
18
Docetaxel Approved May 1996, Investigational Phase 3,Phase 1,Phase 2 114977-28-5 148124 9877265
19
Doxil Approved June 1999 Phase 3,Phase 2 31703
20 Topoisomerase Inhibitors Phase 3,Phase 2
21 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
22 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
23 Anti-Infective Agents Phase 3,Phase 2,Phase 1
24 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
25 Antimetabolites Phase 3,Phase 2,Phase 1
26 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
27 Antiviral Agents Phase 3,Phase 2,Phase 1
28 pancreatic polypeptide Phase 3,Phase 1
29 interferons Phase 2, Phase 3,Phase 1
30 Analgesics Phase 3,Phase 1,Phase 2
31 Alkylating Agents Phase 3,Phase 2
32 Mitomycins Phase 3,Phase 2
33 Adjuvants, Anesthesia Phase 3
34 Adjuvants, Immunologic Phase 3,Phase 2,Phase 1
35 Folic Acid Antagonists Phase 3,Phase 2
36 Narcotics Phase 3
37 Albumin-Bound Paclitaxel Phase 3,Phase 1,Phase 2
38 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
39 Dermatologic Agents Phase 3,Phase 2
40 Analgesics, Opioid Phase 3
41 Anesthetics Phase 3
42 Vaccines Phase 3,Phase 2,Phase 1
43 Anesthetics, General Phase 3
44 Anesthetics, Intravenous Phase 3
45 Peripheral Nervous System Agents Phase 3,Phase 1,Phase 2
46 Vitamin B Complex Phase 3,Phase 2
47 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
48 Liver Extracts Phase 3,Phase 1
49 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
50 Antimitotic Agents Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 114)
id Name Status NCT ID Phase
1 Radiation Therapy or Surgery in Treating Patients Receiving Chemotherapy for Bladder Cancer Unknown status NCT00867347 Phase 3
2 Surgery With or Without Chemotherapy in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer Unknown status NCT00003725 Phase 3
3 Combination Chemotherapy in Treating Patients With Bladder Cancer Completed NCT00003701 Phase 3
4 Mycobacterial Cell Wall-DNA Complex in Treatment of BCG-refractory Patients With Non-muscle Invasive Bladder Cancer Completed NCT00406068 Phase 2, Phase 3
5 Efficacy Study of Adding Chemotherapy to Radiotherapy for Treating Bladder Cancer. Completed NCT00330499 Phase 3
6 Radiation Therapy With or Without Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer Completed NCT00024349 Phase 3
7 Cisplatin Plus Gemcitabine With or Without Paclitaxel in Treating Patients With Stage IV Urinary Tract Cancer Completed NCT00022191 Phase 3
8 Two-Drug Combination Chemotherapy Compared With Four-Drug Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium Completed NCT00003376 Phase 3
9 Combination Chemotherapy in Treating Patients With Transitional Cell Cancer of the Urothelium Completed NCT00014274 Phase 2, Phase 3
10 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
11 S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer Recruiting NCT03091660 Phase 3
12 Bladder Cancer Adjuvant Radiotherapy Trial Recruiting NCT02951325 Phase 3
13 Study to Evaluate the Efficacy and Safety Of Intravesical Nanoxel®M In BCG Refractory NMIBC Recruiting NCT02982395 Phase 3
14 An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer Recruiting NCT02632409 Phase 3
15 Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Active, not recruiting NCT00942331 Phase 3
16 A Study of Intravesical Apaziquone as a Surgical Adjuvant in Patient Undergoing TURBT Active, not recruiting NCT02563561 Phase 3
17 Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer Terminated NCT01438112 Phase 2, Phase 3
18 Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder Terminated NCT01310803 Phase 3
19 Hyperthermia Treatment in Conjunction With Mitomycin C Versus Bacillus Calmette-Guérin Immunotherapy (BCG) for Superficial Bladder Cancer Terminated NCT00384891 Phase 3
20 Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer Terminated NCT01200992 Phase 3
21 Gemcitabine Hydrochloride, Cisplatin, and Sunitinib Malate as First-Line Therapy in Treating Patients With Locally Advanced And/or Metastatic Transitional Cell Carcinoma of the Urothelium Unknown status NCT01089088 Phase 2
22 Carboplatin and Gemcitabine Hydrochloride With or Without Vandetanib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urinary Tract Cancer Unknown status NCT01191892 Phase 2
23 Sunitinib Malate in Treating Patients With Locally Recurrent, Locally Advanced, Unresectable, or Metastatic Urinary Tract Cancer Unknown status NCT01118039 Phase 2
24 Surgery Plus Combination Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Urinary Tract Unknown status NCT00006111 Phase 2
25 Dose Dense MVAC for Muscle Invasive Bladder Cancer Completed NCT01031420 Phase 2
26 Gemcitabine, Cisplatin, and Sunitinib (GC-S) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer Completed NCT00847015 Phase 2
27 Dose-Dense MVAC With Pegfilgrastim Support in Subjects With Muscle-Invasive Urothelial Carcinoma Completed NCT00808639 Phase 2
28 Sunitinib in Treating Patients With Locally Advanced Bladder Cancer Completed NCT00526656 Phase 2
29 Paclitaxel and Radiation Therapy With or Without Trastuzumab in Treating Patients Who Have Undergone Surgery for Bladder Cancer Completed NCT00238420 Phase 1, Phase 2
30 Cisplatin, Bevacizumab, and Gemcitabine Followed by Surgery, Bevacizumab, and Paclitaxel in Treating Patients With Locally Advanced Nonmetastatic Bladder Cancer That Can Be Removed By Surgery Completed NCT00268450 Phase 2
31 Combination Chemotherapy in Treating Patients With Stage II Bladder Cancer Completed NCT00002919 Phase 2
32 S0219, Combination Chemotherapy Followed By Observation or Surgery in Patients With Stage II or Stage III Cancer of the Urothelium Completed NCT00045630 Phase 2
33 Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Function Completed NCT00478361 Phase 2
34 Sunitinib in Treating Patients With Progressive Metastatic Transitional Cell Cancer of the Urothelium Completed NCT00397488 Phase 2
35 S0306, Irinotecan in Treating Patients With Recurrent or Refractory Advanced Transitional Cell Cancer of the Urothelium Previously Treated With Chemotherapy Completed NCT00066612 Phase 2
36 Gemcitabine Hydrochloride, Cisplatin, and Temsirolimus as First-Line Therapy in Treating Patients With Locally Advanced and/or Metastatic Transitional Cell Cancer of the Urothelium Completed NCT01090466 Phase 1, Phase 2
37 S0031, ZD 1839 in Treating Patients With Advanced Cancer of the Urinary Tract Completed NCT00014144 Phase 2
38 VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the Urothelium Completed NCT00407485 Phase 2
39 Intravesical Administration of rAd-IFN/Syn3 in Patients With BCG-Refractory or Relapsed Bladder Cancer Completed NCT01687244 Phase 2
40 Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium and Decreased Kidney Function Completed NCT00005644 Phase 2
41 Ixabepilone in Treating Patients With Advanced Urinary Tract Cancer Completed NCT00021099 Phase 2
42 Pazopanib in Treating Patients With Metastatic Urothelial Cancer Completed NCT00471536 Phase 2
43 Nitrocamptothecin in Treating Patients With Metastatic Cancer of the Urinary Tract Completed NCT00006026 Phase 2
44 SCH 66336 Plus Gemcitabine in Treating Patients With Advanced Cancer of the Urinary Tract Completed NCT00006351 Phase 2
45 Pemetrexed Disodium and Gemcitabine in Treating Patients With Advanced Cancer of the Urothelium Completed NCT00053209 Phase 2
46 Neoadjuvant Ifosfamide, Doxorubicin, Gemcitabine, and Cisplatin in Treating Patients Who Are Undergoing Radical Cystectomy for Locally Advanced Carcinoma (Cancer) of the Urothelium Completed NCT00080795 Phase 2
47 S0121, Neoadjuvant Carboplatin, Paclitaxel, and Gemcitabine Followed by Cisplatin and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Carcinoma of the Urothelium Completed NCT00055835 Phase 2
48 Influence of Hyaluronic Acid on Bacillus Calmette-Guérin Local Side Effects Completed NCT02207608 Phase 2
49 Pazopanib Hydrochloride in Treating Patients With Metastatic Urethral Cancer or Bladder Cancer That Has Relapsed or Not Responded to Treatment Completed NCT01031875 Phase 2
50 Bacillus of Calmette and Guerin (BCG) Versus Gemcitabine For Intravesical Therapy In High Risk Superficial Bladder Cancer Completed NCT00696579 Phase 1, Phase 2

Search NIH Clinical Center for Invasive Bladder Transitional Cell Carcinoma

Genetic Tests for Invasive Bladder Transitional Cell Carcinoma

Anatomical Context for Invasive Bladder Transitional Cell Carcinoma

Publications for Invasive Bladder Transitional Cell Carcinoma

Articles related to Invasive Bladder Transitional Cell Carcinoma:

id Title Authors Year
1
Detection of specific chromosomal aberrations in urine using BCA-1 (oligo-CGH-array) enhances diagnostic sensitivity and predicts the aggressiveness of non-muscle-invasive bladder transitional cell carcinoma. ( 24196429 )
2013
2
Overexpression of RING box protein-1 (RBX1) associated with poor prognosis of non-muscle-invasive bladder transitional cell carcinoma. ( 23609182 )
2013
3
Parallel proteomic analysis in muscle-invasive bladder transitional cell carcinoma and cancer-related stroma. ( 23479173 )
2013
4
[Expression analysis of NOTCH1/HES1/PTEN signaling pathway in invasive bladder transitional cell carcinoma]. ( 22781569 )
2012
5
Proteomics research on muscle-invasive bladder transitional cell carcinoma. ( 21645413 )
2011
6
Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma. ( 17222615 )
2007
7
Efficacy and tolerability of concurrent weekly low dose cisplatin during radiation treatment of localised muscle invasive bladder transitional cell carcinoma: a report of two sequential Phase II studies from the Trans Tasman Radiation Oncology Group. ( 17011058 )
2006
8
Structural alteration of p53 protein in patients with muscle invasive bladder transitional cell carcinoma. ( 11696726 )
2001

Variations for Invasive Bladder Transitional Cell Carcinoma

Cosmic variations for Invasive Bladder Transitional Cell Carcinoma:

9 (show top 50) (show all 395)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM1600408 TSC1 urinary tract,bladder,carcinoma,transitional cell carcinoma c.663+1G>A p.fs*? 10
2 COSM10660 TP53 urinary tract,bladder,carcinoma,transitional cell carcinoma c.818G>A p.R273H 10
3 COSM10788 TP53 urinary tract,bladder,carcinoma,transitional cell carcinoma c.764T>G p.I255S 10
4 COSM11123 TP53 urinary tract,bladder,carcinoma,transitional cell carcinoma c.838A>G p.R280G 10
5 COSM10687 TP53 urinary tract,bladder,carcinoma,transitional cell carcinoma c.527G>A p.C176Y 10
6 COSM10722 TP53 urinary tract,bladder,carcinoma,transitional cell carcinoma c.853G>A p.E285K 10
7 COSM10751 TP53 urinary tract,bladder,carcinoma,transitional cell carcinoma c.772G>C p.E258Q 10
8 COSM10812 TP53 urinary tract,bladder,carcinoma,transitional cell carcinoma c.722C>T p.S241F 10
9 COSM43753 TP53 urinary tract,bladder,carcinoma,transitional cell carcinoma c.560-1G>A p.? 10
10 COSM43951 TP53 urinary tract,bladder,carcinoma,transitional cell carcinoma c.643A>G p.S215G 10
11 COSM43687 TP53 urinary tract,bladder,carcinoma,transitional cell carcinoma c.641A>G p.H214R 10
12 COSM10728 TP53 urinary tract,bladder,carcinoma,transitional cell carcinoma c.839G>A p.R280K 10
13 COSM10662 TP53 urinary tract,bladder,carcinoma,transitional cell carcinoma c.743G>A p.R248Q 10
14 COSM10704 TP53 urinary tract,bladder,carcinoma,transitional cell carcinoma c.844C>T p.R282W 10
15 COSM10646 TP53 urinary tract,bladder,carcinoma,transitional cell carcinoma c.725G>A p.C242Y 10
16 COSM10814 TP53 urinary tract,bladder,carcinoma,transitional cell carcinoma c.832C>G p.P278A 10
17 COSM43708 TP53 urinary tract,bladder,carcinoma,transitional cell carcinoma c.422G>A p.C141Y 10
18 COSM10893 TP53 urinary tract,bladder,carcinoma,transitional cell carcinoma c.824G>A p.C275Y 10
19 COSM44886 TP53 urinary tract,bladder,carcinoma,transitional cell carcinoma c.807C>T p.S269S 10
20 COSM6932 TP53 urinary tract,bladder,carcinoma,transitional cell carcinoma c.733G>A p.G245S 10
21 COSM43965 TP53 urinary tract,bladder,carcinoma,transitional cell carcinoma c.734G>C p.G245A 10
22 COSM44130 TP53 urinary tract,bladder,carcinoma,transitional cell carcinoma c.477C>T p.A159A 10
23 COSM44192 TP53 urinary tract,bladder,carcinoma,transitional cell carcinoma c.272G>A p.W91* 10
24 COSM44115 TP53 urinary tract,bladder,carcinoma,transitional cell carcinoma c.350G>A p.G117E 10
25 COSM10656 TP53 urinary tract,bladder,carcinoma,transitional cell carcinoma c.742C>T p.R248W 10
26 COSM10992 TP53 urinary tract,bladder,carcinoma,transitional cell carcinoma c.844C>G p.R282G 10
27 COSM45261 TP53 urinary tract,bladder,carcinoma,transitional cell carcinoma c.720T>A p.S240R 10
28 COSM43714 TP53 urinary tract,bladder,carcinoma,transitional cell carcinoma c.836G>A p.G279E 10
29 COSM44111 TP53 urinary tract,bladder,carcinoma,transitional cell carcinoma c.574C>A p.Q192K 10
30 COSM11084 TP53 urinary tract,bladder,carcinoma,transitional cell carcinoma c.517G>A p.V173M 10
31 COSM46304 TP53 urinary tract,bladder,carcinoma,transitional cell carcinoma c.357C>G p.A119A 10
32 COSM45917 TP53 urinary tract,bladder,carcinoma,transitional cell carcinoma c.364G>T p.V122L 10
33 COSM10735 TP53 urinary tract,bladder,carcinoma,transitional cell carcinoma c.638G>A p.R213Q 10
34 COSM46107 TP53 urinary tract,bladder,carcinoma,transitional cell carcinoma c.599A>T p.N200I 10
35 COSM10659 TP53 urinary tract,bladder,carcinoma,transitional cell carcinoma c.817C>T p.R273C 10
36 COSM10779 TP53 urinary tract,bladder,carcinoma,transitional cell carcinoma c.818G>T p.R273L 10
37 COSM10988 TP53 urinary tract,bladder,carcinoma,transitional cell carcinoma c.772G>A p.E258K 10
38 COSM43704 TP53 urinary tract,bladder,carcinoma,transitional cell carcinoma c.405C>T p.C135C 10
39 COSM43899 TP53 urinary tract,bladder,carcinoma,transitional cell carcinoma c.434T>C p.L145P 10
40 COSM10645 TP53 urinary tract,bladder,carcinoma,transitional cell carcinoma c.527G>T p.C176F 10
41 COSM10731 TP53 urinary tract,bladder,carcinoma,transitional cell carcinoma c.707A>G p.Y236C 10
42 COSM10648 TP53 urinary tract,bladder,carcinoma,transitional cell carcinoma c.524G>A p.R175H 10
43 COSM44446 TP53 urinary tract,bladder,carcinoma,transitional cell carcinoma c.873G>C p.K291N 10
44 COSM44986 TP53 urinary tract,bladder,carcinoma,transitional cell carcinoma c.302A>G p.K101R 10
45 COSM46032 TP53 urinary tract,bladder,carcinoma,transitional cell carcinoma c.836G>T p.G279V 10
46 COSM45289 TP53 urinary tract,bladder,carcinoma,transitional cell carcinoma c.619G>T p.D207Y 10
47 COSM44683 TP53 urinary tract,bladder,carcinoma,transitional cell carcinoma c.652G>A p.V218M 10
48 COSM43844 TP53 urinary tract,bladder,carcinoma,transitional cell carcinoma c.613T>G p.Y205D 10
49 COSM43606 TP53 urinary tract,bladder,carcinoma,transitional cell carcinoma c.734G>A p.G245D 10
50 COSM10724 TP53 urinary tract,bladder,carcinoma,transitional cell carcinoma c.839G>C p.R280T 10

Expression for Invasive Bladder Transitional Cell Carcinoma

Search GEO for disease gene expression data for Invasive Bladder Transitional Cell Carcinoma.

Pathways for Invasive Bladder Transitional Cell Carcinoma

GO Terms for Invasive Bladder Transitional Cell Carcinoma

Biological processes related to Invasive Bladder Transitional Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 13)
id Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.69 CDKN1A NOTCH1 TP53
2 Ras protein signal transduction GO:0007265 9.52 CDKN1A TP53
3 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006977 9.49 CDKN1A TP53
4 animal organ regeneration GO:0031100 9.48 CDKN1A NOTCH1
5 positive regulation of reactive oxygen species metabolic process GO:2000379 9.46 CDKN1A TP53
6 cellular response to ionizing radiation GO:0071479 9.43 CDKN1A TP53
7 intrinsic apoptotic signaling pathway GO:0097193 9.4 CDKN1A TP53
8 intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator GO:0042771 9.37 CDKN1A TP53
9 cellular response to gamma radiation GO:0071480 9.32 CDKN1A TP53
10 response to X-ray GO:0010165 9.26 CDKN1A TP53
11 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.16 CDKN1A TP53
12 replicative senescence GO:0090399 8.96 CDKN1A TP53
13 signal transduction by p53 class mediator GO:0072331 8.62 CDKN1A TP53

Molecular functions related to Invasive Bladder Transitional Cell Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein kinase binding GO:0019901 8.8 CDKN1A KIF11 TP53

Sources for Invasive Bladder Transitional Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....